Is XBIOW or ORCC a better dividend investment in 2026?

XBIOW currently yields 11.40% with a 5% 5-year dividend growth rate. ORCC yields 9.79% with 5% growth. The better choice depends on your goal: XBIOW offers higher current income.

What is the dividend yield difference between XBIOW and ORCC?

XBIOW has a forward dividend yield of 11.40% ($2.00/share annually). ORCC yields 9.79% ($1.32/share annually). The yield gap is 1.61 percentage points.

Home › Compare › XBIOW vs ORCC

XBIOW vs ORCC: Dividend Comparison 2026

XBIOW yields 11.40% · ORCC yields 9.79%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 XBIOW wins by $21.1K in total portfolio value

INVESTMENT

TIME HORIZON10 years

XBIOW

● Live price

11.40%

Share price

$17.54

Annual div

$2.00

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$42.5K

Annual income

$2,326.31

Full XBIOW calculator →

ORCC

● Live price

9.79%

Share price

$13.48

Annual div

$1.32

5Y div CAGR

-50%

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$21.4K

Annual income

$1.04

Full ORCC calculator →

Portfolio growth — XBIOW vs ORCC

📍 XBIOW pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	XBIOW	ORCC
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, XBIOW + ORCC cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

XBIOW pays

ORCC pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

XBIOW

Annual income on $10K today (after 15% tax)

$969.21/yr

After 10yr DRIP, annual income (after tax)

$1,977.36/yr

ORCC

Annual income on $10K today (after 15% tax)

$832.34/yr

After 10yr DRIP, annual income (after tax)

$0.88/yr

At 15% tax rate, XBIOW beats the other by $1,976.48/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of XBIOW + ORCC for your $10,000?

XBIOW: 50%ORCC: 50%

100% ORCC50/50100% XBIOW

Portfolio after 10yr

$31.9K

Annual income

$1,163.68/yr

Blended yield

3.64%

📊

Analyst Conviction Gap

Where Wall Street is most bullish on ORCC right now

XBIOW

No analyst data

Altman Z

-29.7

Piotroski

3/9

ORCC

Analyst Ratings

Buy

Hold

Sell

Consensus: Buy

Price Target

$16.00

+18.7% upside vs current

Range: $16.00 — $16.00

Altman Z

0.5

Piotroski

5/9

Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

XBIOW buys

ORCC buys

Politician	Chamber	Ticker	Type	Amount	Date
Trey Hollingsworth	🏢 House	$ORCC	▲ Buy	$15,001 - $50,000	2022-06-23
Trey Hollingsworth	🏢 House	$ORCC	▲ Buy	$250,001 - $500,000	2022-06-16
Trey Hollingsworth	🏢 House	$ORCC	▲ Buy	$15,001 - $50,000	2022-06-14
Trey Hollingsworth	🏢 House	$ORCC	▲ Buy	$50,001 - $100,000	2022-06-13
Trey Hollingsworth	🏢 House	$ORCC	▲ Buy	$50,001 - $100,000	2022-06-10
Trey Hollingsworth	🏢 House	$ORCC	▲ Buy	$15,001 - $50,000	2022-06-09
Trey Hollingsworth	🏢 House	$ORCC	▲ Buy	$15,001 - $50,000	2022-06-08
Trey Hollingsworth	🏢 House	$ORCC	▲ Buy	$50,001 - $100,000	2022-06-03
Trey Hollingsworth	🏢 House	$ORCC	▲ Buy	$15,001 - $50,000	2022-05-24
Trey Hollingsworth	🏢 House	$ORCC	▲ Buy	$100,001 - $250,000	2022-05-20

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricXBIOWORCC

Forward yield	11.40% ✓	9.79%
Annual dividend / share	$2.00 ✓	$1.32
Payout ratio	50%	50%
1-year div growth	0%	0%
5-year div CAGR	0% ✓	-50%
Portfolio after 10y	$42.5K ✓	$21.4K
Annual income after 10y	$2,326.31 ✓	$1.04
Total dividends collected	$17.2K ✓	$1.0K
Payment frequency	quarterly	quarterly
Sector	Stock	BDC

Year-by-year: XBIOW vs ORCC ($10,000, DRIP)

Year	XBIOW Portfolio	XBIOW Income/yr	ORCC Portfolio	ORCC Income/yr	Gap
1← crossover	$11,840	$1,140.25	$11,190	$489.61	+$650.00 → XBIOW
2	$13,931	$1,261.76	$12,229	$256.01	+$1.7K → XBIOW
3	$16,293	$1,387.43	$13,216	$130.74	+$3.1K → XBIOW
4	$18,951	$1,516.57	$14,207	$66.02	+$4.7K → XBIOW
5	$21,926	$1,648.49	$15,234	$33.17	+$6.7K → XBIOW
6	$25,243	$1,782.51	$16,317	$16.62	+$8.9K → XBIOW
7	$28,928	$1,917.94	$17,468	$8.32	+$11.5K → XBIOW
8	$33,007	$2,054.14	$18,695	$4.16	+$14.3K → XBIOW
9	$37,508	$2,190.46	$20,006	$2.08	+$17.5K → XBIOW
10	$42,460	$2,326.31	$21,407	$1.04	+$21.1K → XBIOW

XBIOW vs ORCC: Complete Analysis 2026

XBIOW — Stock

Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing XCART, a personalized chimeric antigen receptor T cell (CAR T) platform technology engineered to target patient-specific tumor neoantigens. The company engages in the development of biologic drugs and therapeutics. It advances cell-based therapeutics targeting the B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. In addition, the company leveraging PolyXen, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. It has collaboration agreements with Takeda Pharmaceutical Co. Ltd., Serum Institute of India Limited, and PJSC Pharmsynthez. Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts.

Full XBIOW Calculator →

ORCC — BDC

Owl Rock Capital Corporation is a business development company. The fund makes investments in senior secured or unsecured loans, subordinated loans or mezzanine loans and also considers equity-related securities including warrants and preferred stocks also pursues preferred equity investments and common equity investments. Within private equity, it seeks to invest in growth, acquisitions, market or product expansion, refinancings and recapitalizations. It seeks to invest in middle market companies based in the United States, with EBITDA between $10 million and $250 million annually and/or annual revenue of $50 million and $2.5 billion at the time of investment.

Full ORCC Calculator →

📬

Get this XBIOW vs ORCC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

XBIOW vs SCHD XBIOW vs JEPI XBIOW vs O XBIOW vs KO XBIOW vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.